

SARS-CoV-2 Spike Protein–Targeted Antibodies and COVID-19–Related Outcomes



How are levels of SARS-CoV-2 antibodies related to risk of subsequent SARS-CoV-2 infection and adverse outcomes?



Background


Testing for antibodies that target SARS-CoV-2 spike proteins is not currently recommended by the US Centers for Disease Control and Prevention and, thus, is not widely used in clinical decision-making. However, these antibodies may have implications for subsequent COVID-19–related outcomes, especially among high-risk patient groups.



Methods and Results

Medical records of 195,446 American adults who received SARS-CoV-2 spike protein–targeted antibody testing between November 2020 and December 2021 were reviewed for evidence of subsequent SARS-CoV-2 infection and adverse outcomes.¹

Risk of SARS-CoV-2 infection and adverse outcomes¹ Detectable vs nondetectable antibody levels



Compared with those with nondetectable levels, individuals with detectable levels of antibodies that target SARS-CoV-2 spike proteins were less likely to experience subsequent infection and adverse outcomes.

1. Kaufman HW, Letovsky S, Meyer WA III, et al. SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes. *Front Public Health*. 2023;11. doi:10.3389/fpubh.2023.1193246

For more information about Quest Diagnostics publications, please visit the [Clinical Education Center](#).